Sanjay Gandhi Postgraduate Institute of Medical Sciences

The Postgraduate Institute for Medicine and VieCure Announce a Partnership to Provide CME to Users of the VieCure Platform through Internet Search and Learn

Retrieved on: 
Monday, December 19, 2022
Software, Internet, Oncology, Data Management, Training, Technology, Other Education, Continuing, Artificial Intelligence, Health Technology, Education, Health, Accreditation Council for Continuing Medical Education, NGS, Internet, Continuing medical education, Pharmacist, PIM, Patient, Education, Optometry, CME, Health, Partnership, AMA, Diagnosis, Postgraduate Institute of Medicine, Marketing, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Medicine, Social, Failure, Degenerative disease, Outcome, Multimedia, Accreditation Council, Database, Practitioner, Physician, Research, ACCME, Intelligence, Dentist, Tutoring, Medical imaging, Accreditation, Cancer

Using this model, users of the VieCure platform will be able to claim CME credit for researching the new and emerging therapies for patients with cancer.

Key Points: 
  • Using this model, users of the VieCure platform will be able to claim CME credit for researching the new and emerging therapies for patients with cancer.
  • Next generation sequencing (NGS), which identifies the genomic drivers of a patient’s disease, is increasingly guiding decision-making in cancer care.
  • The VieCure platform, a next-generation artificial intelligence-enabled clinical decision support tool, translates this data for busy providers.
  • The VieCure contracted cancer center network now includes more than 100 locations in the United States, the Bahamas and Antigua.

ACTIVE HEALTH FOODS, INC. CONTINUES TO BUILD WORLD CLASS MEDICAL BOARD ADDING DRS. GALITZER AND ROTHENBERG

Retrieved on: 
Thursday, June 23, 2022
GLOBE, Physician, Patient, University, Stem cell, Medical school, Industry, American Health, Program, Columbia University, Regenerative medicine, BIO, Research, Energy medicine, College of Physicians and Surgeons, American Board of Commissioners for Foreign Missions, OTC, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Health, Board, UC San Diego School of Medicine, Cancer, School, Emergency medicine, Education, University of California, CA, Medical device, Hospital, Director, Surgeon

Dr. Galitzer is the medical director of The American Health Institute, an organization dedicated to education and research in the areas of anti-aging medicine and cancer.

Key Points: 
  • Dr. Galitzer is the medical director of The American Health Institute, an organization dedicated to education and research in the areas of anti-aging medicine and cancer.
  • The American Health Institutes medical office is located in Los Angeles, California.
  • Dr. Rothenberg was the 10th Medical Doctor in the world to be recognized by the American Board of Anti-Aging and Regenerative Medicine.
  • Over the past 10 years Dr. Rothenberg lectured worldwide on Preventive and Regenerative Medicine, Hormone Optimization and Stem Cells.

Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer

Retrieved on: 
Wednesday, May 25, 2022
Acute myeloid leukemia, DNA, HCC, Neoplasm, Sanjay Gandhi Postgraduate Institute of Medical Sciences, PGIMER, Molecular logic gate, Doctor of Philosophy, Leadership, AML, Patient, Infection, AACR, Neurology, Synthetic biology, Therapy, Society, Tissue engineering, Adult, Joint Planning and Development Office, Cell, Gene, SAN, IND, Onyx, Medical education, Biotechnology, American Association for Cancer Research, Spark, Hepatocellular carcinoma, Program, Bluerock Wildland Provincial Park, ASH, Colorectal cancer, American Society of Gene and Cell Therapy, American Association, Intelligence, CAR, Cancer, Postgraduate Institute of Medical Education and Research, Multi-armed bandit, Investigational New Drug, GLOBE, Pharmaceutical industry, Vaccine, Medical imaging, Exelixis, Northwestern University, MD

SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced the appointment of Kanya Rajangam, MD, PhD, as Chief Medical and Development Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced the appointment of Kanya Rajangam, MD, PhD, as Chief Medical and Development Officer.
  • As Chief Medical and Development Officer, Dr. Rajangam will be broadly responsible for leading the development and regulatory strategy to rapidly advance Senti Bio's off-the-shelf CAR-NK cell oncology programs into and through clinical development.
  • Dr. Rajangam joins Senti Bio from Nkarta Therapeutics where, as chief medical officer, she was responsible for clinical development of CAR-NK cell therapies for oncology.
  • Prior to that, Dr. Rajangam was chief medical officer of Cleave Biosciences, where she led oncology clinical development programs.

New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance

Retrieved on: 
Saturday, April 23, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CEO, Least squares, Pain, Government, Medicine, Marketing, Sanjay Gandhi Postgraduate Institute of Medical Sciences, COVID-19, Social responsibility, University, Intention, Diagnosis, Infection, CNS, RNA, Therapy, Death, Patient, Hokkaido University, Global Health, University of Tokyo, 2021 Essex County Council election, Coronavirus, Safety, Industry, HIV, Omicron, Severe acute respiratory syndrome coronavirus 2, Health, National Center for Health Research, Institute, Congress, Pharmaceutical industry, Vaccine, European, Shionogi

These new data showed:

Key Points: 
  • These new data showed:
    S-217622 demonstrated rapid clearance of the infectious SARS-CoV-2 virus.
  • S-217622 shortened infectious virus shedding by 1-2 days versus placebo.
  • Its main purpose was to confirm the antiviral effect and clinical symptom improvement of S-217622 when orally administered once daily for five days, versus placebo.
  • Additionally, in the preliminary in vitro study, S-217622 exhibited similar antiviral activity against the Omicron subvariant BA.2 and other existing variants.

Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation

Retrieved on: 
Monday, February 28, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Courage, Liver cancer, Twitter, Maryland School, Nerve, Entrepreneurship, NASDAQ, Alternating electric field therapy, Physics, Toxicity, University, Research, Fundamental, Biology, Medicine, Clinical trial, Glioblastoma, Pancreatic cancer, Israel Prize, Adult, LinkedIn, Multimedia, Mesothelioma, Skin, University of Maryland School of Medicine, Cancer, Stomach, Biophysics, Patient, Survival, Ovarian cancer, Large-cell lung carcinoma, Physiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Management, Medical imaging, Pharmaceutical industry, Technion – Israel Institute of Technology, Technology, Novocure, Professor Yoram Palti, Tumor Treating Fields, NOVOCURE, PROFESSOR YORAM PALTI, TUMOR TREATING FIELDS

Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocures Founder and Chief Technology Officer, has been selected to receive the 2022 Israel Prize in the field of entrepreneurship and technological innovation.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocures Founder and Chief Technology Officer, has been selected to receive the 2022 Israel Prize in the field of entrepreneurship and technological innovation.
  • View the full release here: https://www.businesswire.com/news/home/20220228005281/en/
    In 2000, Professor Yoram Palti set up a laboratory in his basement in the Israeli port city of Haifa and founded Novocure.
  • Professor Palti demonstrated great courage as he pursued a truly novel approach to cancer treatment, said Asaf Danziger, Novocures CEO.
  • Professor Yoram Palti founded Novocure in 2000, has been our Chief Technology Officer, serving as a consultant, since 2000 and was a director of Novocure from 2002 to 2018.

AudioSense Hearing, Balance & Concussion Celebrates Move to a New Exciting Location and Expanding Team

Retrieved on: 
Friday, January 21, 2022
Patient, Research, University, Dementia, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Breast implant, International development, Hearing, Medicine, Davenport Road, Falls, Concussion, Neuroscience, Dalhousie University, GLOBE, Health, Chantal, Bucksbaum Institute for Clinical Excellence, Hearing loss, Infant, Marketing, Music, Quality of life, Hospital for Sick Children, Depression, University of Ottawa Heart Institute, Salima, Institute, Social media, Dentistry, Sales, Audiology, Tinnitus

AudioSense Hearing, Balance & Concussion is a specialized audiology clinic that provides high-quality, holistic hearing care in Toronto to those suffering from hearing difficulties, balance impairments and concussion.

Key Points: 
  • AudioSense Hearing, Balance & Concussion is a specialized audiology clinic that provides high-quality, holistic hearing care in Toronto to those suffering from hearing difficulties, balance impairments and concussion.
  • Highlights of the new location include:
    To see the new AudioSense clinic or learn more from the growing team of talented audiologists, visit www.audiosense.ca , or book an appointment today via phone at 416.901.4770, or, email [email protected].
  • The AudioSense team is on a mission to innovate, educate, and offer the best care for hearing, balance, and concussion management possible.
  • Alternatively, if you have any queries or would like to book an appointment, please call the team at 416.901.4770 or email them [email protected].

FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish

Retrieved on: 
Tuesday, November 16, 2021
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Inflammation, University, Canadian Securities Administrators, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Associate, Medicine, Honours degree, FRA, CSE, Cytokine, U.S. Securities and Exchange Commission, PEA, NASDAQ, Neurodegeneration, Institute, Multiple sclerosis, Department, King's College, Necessary International Initiative, SEDAR, Immunology, Rheumatoid arthritis, Phrase, COVID-19, Research, Forward-looking statement, FSD, University Health Network, Government, Ottawa Hospital Research Institute, Company, Therapy, Degenerative disease, Risk, Drug development, Fine chemical, Pharmaceutical industry

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (FSD Pharma or the Company), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of Eleanor N. Fish, Ph.D., to its Research and Clinical Advisory Board.

Key Points: 
  • FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (FSD Pharma or the Company), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of Eleanor N. Fish, Ph.D., to its Research and Clinical Advisory Board.
  • I am delighted to welcome Dr. Eleanor Fish to our team, said Dr. Lakshmi P. Kotra, B.Pharm.
  • A key aspect of Eleanors research is to better understand the onset and treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.
  • The Company does not undertake to update any forward-looking statements, except to the extent required by applicable securities laws.

Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment

Retrieved on: 
Tuesday, October 19, 2021
Knowledge, Female gendering of AI technologies, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Google Knowledge Graph, Death, Institute, University, Technology, Efficiency, Phrase, Genome, Healthy Living, ICT, Data, Disease, Research, Attention, Time, Quality of life, Medicine, Hospital, Patient, AI, Fujitsu, US, Cancer, Solution, Physician, Environment, Medical imaging, Pharmaceutical industry, Medical device, Health insurance, Dietary supplement, Information technology

With current cancer genomic medicine in Japan, treatment plans are considered based on the patients' unique circumstances, including the type of cancer and the actionable genomic variants detected in cancer cells.

Key Points: 
  • With current cancer genomic medicine in Japan, treatment plans are considered based on the patients' unique circumstances, including the type of cancer and the actionable genomic variants detected in cancer cells.
  • Aichi Cancer Center and Fujitsu will continue cooperation to further enhance the application of AI technology in cancer genomic medicine in order to contribute to further achievements in this field.
  • For cancer treatment, the system can deliver an objective score about the expected level of effectiveness of a planned course of treatment based on the information about the patients' cancer type and genomic variants.
  • During the current verification trials, which were supervised by an expert panel (7) at Aichi Cancer Center, the system was used to evaluate the effects of drug treatment with approximately 450 patients.